Login to Your Account

Santaris Getting $10M Up Front In BMS Drug Discovery Pact

By Cormac Sheridan
Staff Writer

Tuesday, April 16, 2013
Santaris Pharma A/S is getting $10 million up front and could earn up to $90 million more in per-product milestones from a multiproduct drug discovery alliance with Bristol-Myers Squibb Co., based on its Locked Nucleic Acid (LNA) antisense technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription